Neuralstem, Inc. – "Most men would rather deny a hard truth than face it"

Publishing & Media

Share Tweet

Neuralstem, Inc. – "Most men would rather deny a hard truth than face it"

New York, NY / May 28, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) today published a new blog post on the Company's website which was republished on (, written by the Company's President and CEO, Richard Garr. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, Mr. Garr reflects on the treatments currently available to veterans and the recent controversy surrounding long patient wait times for veterans. He writes, "Veteran care is an area of increasing importance to Neuralstem as a company," highlighting spinal cord injury, brain injury and major depressive disorder as key focal points for the Company. Read the full blog post from Richard Garr on

About Neuralstem

Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the Company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The Company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate neurons, possibly reversing pathologies associated with certain central nervous system conditions. The Company has completed a Phase I safety trial evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD). Additional indications might include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit or connect with us on Twitter, Facebook and LinkedIn.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.